Cargando…

Systematic Characterization of the Clinical Relevance of KPNA4 in Pancreatic Ductal Adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with poor prognosis. Karyopherin subunit alpha 4 (KPNA4) is a nuclear transport factor and plays tumor-promoting roles in multiple cancers. However, the roles of KPNA4 in PDAC still remain unknown. This study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bao, Jingpiao, Xu, Chaoliang, Li, Bin, Wu, Zengkai, Shen, Jie, Song, Pengli, Peng, Qi, Hu, Guoyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9002131/ https://www.ncbi.nlm.nih.gov/pubmed/35425701 http://dx.doi.org/10.3389/fonc.2022.834728

Ejemplares similares

Corrigendum: Systematic characterization of the clinical relevance of KPNA4 in pancreatic ductal adenocarcinoma
por: Bao, Jingpiao, et al.
Publicado: (2023)

Dopamine D2 Receptor Signaling Attenuates Acinar Cell Necroptosis in Acute Pancreatitis through the Cathepsin B/TFAM/ROS Pathway
por: Wu, Zengkai, et al.
Publicado: (2022)

Endoplasmic reticulum stress promoted acinar cell necroptosis in acute pancreatitis through cathepsinB-mediated AP-1 activation
por: Han, Xiao, et al.
Publicado: (2022)

Relevance of Immune Infiltration and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma Subtypes
por: Liu, Rong, et al.
Publicado: (2021)

Targeting mTOR in Pancreatic Ductal Adenocarcinoma
por: Iriana, Sentia, et al.
Publicado: (2016)

Non-coding RNAs in Pancreatic Ductal Adenocarcinoma
por: Gong, Ruining, et al.
Publicado: (2020)

Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?
por: Wang, Chenqi, et al.
Publicado: (2022)

Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape
por: Xu, He, et al.
Publicado: (2021)

Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review
por: Wang, Yizhi, et al.
Publicado: (2020)

Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma
por: Hayashi, Hiromitsu, et al.
Publicado: (2021)

Pancreatic Ductal Adenocarcinoma Cortical Mechanics and Clinical Implications
por: Angstadt, Shantel, et al.
Publicado: (2022)

The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma
por: Zhang, Jingchang, et al.
Publicado: (2022)

Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma
por: Zhao, Juan, et al.
Publicado: (2022)

Identification of an Immune-Related Signature for Predicting Prognosis in Patients With Pancreatic Ductal Adenocarcinoma
por: Wang, Weijia, et al.
Publicado: (2021)

Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
por: Awad, Seifeldin, et al.
Publicado: (2020)

The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives
por: Wu, Yang, et al.
Publicado: (2021)

Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021)

OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma
por: Ding, Jinsheng, et al.
Publicado: (2021)

Up-Regulated MISP Is Associated With Poor Prognosis and Immune Infiltration in Pancreatic Ductal Adenocarcinoma
por: Huang, Xinyang, et al.
Publicado: (2022)

Vascularization, Oxygenation, and the Effect of Sunitinib Treatment in Pancreatic Ductal Adenocarcinoma Xenografts
por: Gaustad, Jon-Vidar, et al.
Publicado: (2019)

The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy
por: Principe, Daniel R., et al.
Publicado: (2021)

Corrigendum: Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021)

Development and validation of an MRI-radiomics nomogram for the prognosis of pancreatic ductal adenocarcinoma
por: Xu, Xinsen, et al.
Publicado: (2023)

MRI Feature-Based Nomogram Model for Discrimination Between Non-Hypervascular Pancreatic Neuroendocrine Tumors and Pancreatic Ductal Adenocarcinomas
por: Xu, Jiake, et al.
Publicado: (2022)

Review of the endocrine organ–like tumor hypothesis of cancer cachexia in pancreatic ductal adenocarcinoma
por: Yu, Ying-Chun, et al.
Publicado: (2022)

Characterization of 3D heterocellular spheroids of pancreatic ductal adenocarcinoma for the study of cell interactions in the tumor immune microenvironment
por: Giustarini, Giulio, et al.
Publicado: (2023)

The clinical relevance of the Hippo pathway in pancreatic ductal adenocarcinoma
por: Drexler, Richard, et al.
Publicado: (2020)

Development and Validation of a Nomogram Based on Nutritional Indicators and Tumor Markers for Prognosis Prediction of Pancreatic Ductal Adenocarcinoma
por: Li, Haoran, et al.
Publicado: (2021)

The Necessity of Dissection of No. 14 Lymph Nodes to Patients With Pancreatic Ductal Adenocarcinoma Based on the Embryonic Development of the Head of the Pancreas
por: Qian, Lihan, et al.
Publicado: (2020)

Regulation of Proliferation by a Mitochondrial Potassium Channel in Pancreatic Ductal Adenocarcinoma Cells
por: Peruzzo, Roberta, et al.
Publicado: (2017)

Circulating Chromogranin A Is Cleaved Into Vasoregulatory Fragments in Patients With Pancreatic Ductal Adenocarcinoma
por: Reni, Michele, et al.
Publicado: (2020)

Comparison of Radiomic Features in a Diverse Cohort of Patients With Pancreatic Ductal Adenocarcinomas
por: Permuth, Jennifer B., et al.
Publicado: (2021)

Potential Metabolite Biomarkers for Early Detection of Stage-I Pancreatic Ductal Adenocarcinoma
por: Cao, Yingying, et al.
Publicado: (2022)

Digital quantitative tissue image analysis of hypoxia in resected pancreatic ductal adenocarcinomas
por: Siddiqui, Iram, et al.
Publicado: (2022)

Transcriptional, chromatin, and metabolic landscapes of LDHA inhibitor–resistant pancreatic ductal adenocarcinoma
por: Malvi, Parmanand, et al.
Publicado: (2022)

The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma
por: Lu, Hao, et al.
Publicado: (2022)

Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma
por: Ashok Kumar, Prashanth, et al.
Publicado: (2023)

Loss of Cadherin-11 in pancreatic ductal adenocarcinoma alters tumor-immune microenvironment
por: Sebastian, Aimy, et al.
Publicado: (2023)

Development and Validation of a Nomogram to Predict Survival in Pancreatic Head Ductal Adenocarcinoma After Pancreaticoduodenectomy
por: Peng, Feng, et al.
Publicado: (2021)

The enigmatic helicase DHX9 as a candidate prognostic biomarker for resected pancreatic ductal adenocarcinoma
por: Chen, Le-gao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vcjmc9luopgv8gikg96o9r0dlv